Nexpoint Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Nexpoint Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-450,925	Closed	-$1.71M	–	241
2020 Q1	$1.71M	Hold	450,925	–	–	0.32%	49
2019 Q4	$2.29M	Sell	450,925 -265,955	-37%	-$1.41M	0.17%	76
2019 Q3	$3.62M	Buy	+716,880	New	+$3.58M	0.23%	64

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Nexpoint Asset Management's PGNX Position: Q2 2020 in Review

Nexpoint Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 450,925 shares — an estimated $1.71M sold.

Nexpoint Asset Management first reported a position in PGNX in Q3 2019 and held it in 3 quarters. The position peaked at $3.62M in Q3 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Nexpoint Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Nexpoint Asset Management sold 450,925 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.71M.
Nexpoint Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2019 and held it in 3 quarters.
Nexpoint Asset Management's Progenics Pharmaceuticals Inc position peaked at $3.62M in Q3 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Nexpoint Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.